−1.965SEK
−249.11 MSEK
35.22 MSEK
129.59 M
About ONCOPEPTIDES AB
Sector
CEO
Sofia Heigis
Headquarters
Stockholm
Website
Employees (FY)
57
Founded
2000
ISIN
SE0009414576
FIGI
BBG00FYBPDP1
Oncopeptides AB is a pharmaceutical company, which is involved in the development of targeted therapies for hematological diseases. The firm focuses on its product candidate melflufen, a peptide conjugated alkylator, belonging to a new class of drugs called peptidase enhanced cytotoxics, which targets aminopeptidases and rapidly releases alkylating agents into tumor cells. The company was founded by Rolf Larsson, Rolf Lewensohn, Joachim Gullbo, Kristina Luthman, Hans Ehrsson, and Peter Nygren on September 5, 2000 and is headquartered in Stockholm, Sweden.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ONCO is 4.540 SEK — it has increased by 1.57% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on OMXSTO exchange ONCOPEPTIDES AB stocks are traded under the ticker ONCO.
ONCOPEPTIDES AB is going to release the next earnings report on May 3, 2024. Keep track of upcoming events with our Earnings Calendar.
ONCO stock is 9.61% volatile and has beta coefficient of 0.35. Check out the list of the most volatile stocks — is ONCOPEPTIDES AB there?
One year price forecast for ONCOPEPTIDES AB has a max estimate of 9.975 SEK and a min estimate of 3.920 SEK.
ONCO earnings for the last quarter are −0.44 SEK whereas the estimation was −0.68 SEK which accounts for 34.74% surprise. Estimated earnings for the next quarter are −0.70 SEK. See more details about ONCOPEPTIDES AB earnings.
ONCOPEPTIDES AB revenue for the last quarter amounts to 26.00 M SEK despite the estimated figure of 25.28 M SEK. In the next quarter revenue is expected to reach 28.96 M SEK.
Yes, you can track ONCOPEPTIDES AB financials in yearly and quarterly reports right on TradingView.
ONCO stock has risen by 30.41% compared to the previous week, the month change is a 52.63% rise, over the last year ONCOPEPTIDES AB has showed a 42.53% decrease.
ONCO net income for the last quarter is −81.21 M SEK, while the quarter before that showed −40.54 M SEK of net income which accounts for −100.31% change. Track more ONCOPEPTIDES AB financial stats to get the full picture.
Today ONCOPEPTIDES AB has the market capitalization of 924.69 M, it has decreased by 11.45% over the last week.
No, ONCO doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ONCO shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade ONCOPEPTIDES AB stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 19, 2024, the company has 57.00 employees. See our rating of the largest employees — is ONCOPEPTIDES AB on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So ONCOPEPTIDES AB technincal analysis shows the buy rating today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating ONCOPEPTIDES AB stock shows the sell signal. See more of ONCOPEPTIDES AB technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on ONCOPEPTIDES AB future price: according to them, ONCO price has a max estimate of 9.98 SEK and a min estimate of 3.92 SEK. Read a more detailed ONCOPEPTIDES AB forecast: see what analysts think of ONCOPEPTIDES AB and suggest that you do with its stocks.